Business Insider

Buy Rating Affirmed for Avidity Biosciences on Promising FSHD Drug Efficacy and Upcoming Data Release

Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Avidity Biosciences (RNA – Research Report). The associated price target remains the same with $50.00. Yanan Zhu has given his Buy ...
STAT

Avidity, FDA reach agreement on accelerated filing of rare disease drug

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Nasdaq

12 Analysts Assess Avidity Biosciences: What You Need To Know

12 analysts have shared their evaluations of Avidity Biosciences (NASDAQ:RNA) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...
Seeking Alpha

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

SAN DIEGO, April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ...